12:00 AM
 | 
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ZD 0473: Began Phase I testing

AnorMed Inc. (TSE:AOM), Langley, B.C.
Product: ZD 0473
Business: Cancer
Therapeutic category: Cytotoxic
Target:...

Read the full 60 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >